Cytochrome P450 enzymes (CYP3A4, CYP2D6, and CYP2C9) (CYP3A4/CYP2D6/CYP2C9)

CYP3A4, CYP2D6, and CYP2C9 are the three most critical members of the Cytochrome P450 enzyme superfamily involved in human drug metabolism. Located primarily in the liver and intestines, these heme-containing enzymes are responsible for the oxidative biotransformation of approximately 60-70% of all clinically used drugs. CYP3A4 is the most abundant and versatile, handling over 50% of marketed drugs, while CYP2D6 and CYP2C9 exhibit significant genetic polymorphism, leading to wide inter-individual variability in drug response. These enzymes are rarely therapeutic targets themselves (with exceptions like Ritonavir used as a CYP3A4 'booster'); instead, they are primary 'antitargets' or metabolic hurdles that dictate a drug's half-life, bioavailability, and safety profile. Understanding their interaction with new chemical entities is a cornerstone of modern pharmacokinetics and personalized medicine.

Other names

Cytochrome P450 3A4Cytochrome P450 2D6Cytochrome P450 2C9CYP3A4CYP2D6CYP2C9Microsomal monooxygenaseXenobiotic-metabolizing enzymes

These enzymes catalyze the oxidation of organic substances, primarily through the insertion of one atom of oxygen into an aliphatic or aromatic substrate (monooxygenase activity). Drugs can act as substrates, inhibitors, or inducers of these enzymes, thereby altering the pharmacokinetic profile of co-administered medications.